Navigation Links
Sitari Pharmaceuticals, First Company Launched Through Avalon Ventures-GlaxoSmithKline Collaboration, Raises up to $10 Million Series A Financing and R&D Support
Date:11/22/2013

SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Avalon Ventures today announced the launch of Sitari Pharmaceuticals, the first company formed by Avalon and GlaxoSmithKline (GSK) under a unique collaboration recently established to fund and launch up to 10 early-stage life science companies in San Diego. Sitari has raised $10 million in Series A financing and R&D support from Avalon Ventures and GSK for the development of novel treatments for celiac disease. Separately, Avalon has also established COI Pharmaceuticals (COI), an unconventional venture-pharma entity that will provide operational support, a fully equipped R&D facility and an experienced leadership team to Sitari and future companies that may be created from the Avalon-GSK collaboration.

"We received an overwhelmingly positive response to the collaboration between GSK and Avalon Ventures, and established COI Pharmaceuticals to support the rapid launch of new companies as we already have an outstanding pipeline of projects to choose from," said Jay Lichter, CEO of COI and Managing Director of Avalon Ventures. "COI is a 'Community of Innovation' that provides an environment where entrepreneurial and scientific risks are encouraged and rewarded for life science inventors with bold ideas. We are attracting and in-licensing innovative discoveries with significant potential for drug development and working with founding scientists to launch promising early-stage companies such as Sitari."

Sitari Pharmaceuticals is targeting the Transglutaminase 2 (TG2) pathway for the development of treatments for multiple disease indications, with an initial focus in celiac disease. Celiac disease is an autoimmune digestive disease caused by intolerance to gluten, a protein found in wheat, rye and barley that damages the small intestine and interferes with absorption of nutrients from food. The company's therapeutic approach ta
'/>"/>

SOURCE Avalon Ventures
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Acquisitions, Conference Participations, Court Rulings, and Product Deliveries - Research Report on Zoetis, Aegerion Pharmaceuticals, Edwards, Community Health Systems, and Air Methods
2. Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
3. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
4. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
5. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
6. ANI Pharmaceuticals, Inc. Announces Date for Third Quarter 2013 Earnings Release
7. Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity
8. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum
9. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
10. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
11. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department of ... grant to University Hospitals (UH) Case Medical Center Seidman ... national model aimed at improving care for patients with ... the project will test a unique model developed at ... late-stage disease, significant comorbidities, or demonstrated need for high ...
(Date:7/10/2014)... , July 10, 2014 Yesterday, ... Research,s (Moberg) medical device manufacturing facility. Rep. Kennedy ... advanced neurological monitors facilitate cutting-edge research in neurological ... Kennedy and mental health advocate, Garen Staglin ... dedicated to fostering fundamental changes that will radically ...
(Date:7/10/2014)... Mass. , July 10, 2014  Decision ... of surveyed infectious disease (ID) specialists are willing ... Company,s Orbactiv (oritavancin) for use as OPAT, approximately ... prescribe these agents to their hospital inpatients. However, ... of OPAT patients are initiated on OPAT following ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... A decreased ability to identify odors might ... disease, while examinations of the eye could indicate ... Alzheimer,s, in the brain, according to the results ... Alzheimer,s Association International Conference 2014 (AAIC 2014) in ... decreased ability to identify odors was significantly associated ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
(Date:7/13/2014)... California (PRWEB) July 13, 2014 Celebrity ... Musico has formed a promotional partnership with Aqua Health ... based Omega-3 EPA supplement . The collaboration was ... a celebrity fitness trainer , actor, model, and ... go-to trainer for A-List celebrities, he has prepared stars ...
(Date:7/13/2014)... July 13, 2014 Hope Palliative & Hospice ... grief support group at the Tamarack Senior Living Community in ... at 10:30 A.M. on the 3rd Wednesdays of every month. ... at the Tamarack Community located at 55 S. Greeley St. ... individuals and there is no cost for the group. ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... ,Age-Related Macular Degeneration Awareness Month, , , SUNDAY, ... its efforts to educate Americans about age-related macular ... Age-Related Macular Degeneration Awareness Month. , AMD -- ... costs the U.S. economy $570 million a year ...
... A mathematical model that looks at different strategies ... and patient isolation may be effective approaches when ... era of superbugs, such as methicillin-resistant Staphylococcus aureas ... over bacterial infections, this type of modeling, if ...
... BOSTON, Feb. 16, 2008 According to the National ... 80 percent of them women. Because the disease causes ... hip fractures, spinal fractures and a whole host of ... as popularly prescribed Fosamax (alendronate sodium), are a class ...
... finding that out of sight, out of mind can no ... our waters. Substances that we use everyday are turning up ... aquatic life and possibly ourselves. , Derek Muir of ... or so chemicals used commercially in the United States and ...
... Ala., Feb. 15 Cory Watson Crowder &,DeGaris, ... Bayer AG on behalf,of plaintiffs throughout the United ... given Trasylol(R) -- a,Bayer-manufactured drug used to prevent ... called CABG or more commonly bypass).,According to CBS ...
... MADISON, N.J., Feb. 15 Wyeth Consumer,Healthcare, a ... announced that Isma,Benattia, MD, has been named Executive ... Dr. Benattia will lead all,aspects of the consumer ... will drive and prioritize the division,s R&D efforts ...
Cached Medicine News:Health News:Don't Lose Sight of Vision Care, Group Urges 2Health News:Mathematical modeling offers new approaches to fight dual-resistant hospital infections 2Health News:Link between treating osteoporosis with bisphosphonates and incidence of bone necrosis examined 2Health News:New findings on emerging contaminants 2Health News:New findings on emerging contaminants 3Health News:New findings on emerging contaminants 4Health News:New findings on emerging contaminants 5Health News:60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG 2Health News:Wyeth Consumer Healthcare Names New Head of Global R&D 2
Straight 22 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 4.9 inches...
Straight shafts with 13 mm crisscross serrated platform with polished finish. Wide serrated handle....
Straight shafts with 6.5 mm tying platform. Crisscross serrated 1mm tips. Scalloped handle with dull finish....
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Medicine Products: